Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority, received a delegation from Abdi Ibrahim Pharmaceuticals, headed by Dr. Tasbolat Oglu Suha, Member of the Board of Directors and Chief Executive Officer of the company, in the presence of Mr. Olgun Koksal, Executive Board Member and Head of International Markets, and Mr. Shorouk Hamed, Commercial Attaché at the Egyptian Commercial Representation.
The meeting aimed to explore opportunities for joint cooperation and discuss mechanisms to support the company’s presence in the Egyptian market.
At the beginning of the meeting, Dr. El-Ghamrawy welcomed the company’s delegation, emphasizing the Authority’s commitment to supporting cooperation with leading companies in the pharmaceutical industry.
Dr. El-Ghamrawy highlighted that the Egyptian Drug Authority places great importance on strengthening cooperation with major global pharmaceutical companies, contributing to the state’s plans to localize pharmaceutical manufacturing and increase domestic production capacity. He noted that the Egyptian market represents a promising strategic platform for attracting pharmaceutical investments, given its advanced regulatory and oversight framework.
He added that the Authority is working to create a supportive regulatory environment for investment and encourages the transfer of modern technologies and the localization of advanced pharmaceutical industries. These efforts aim to enhance Egypt’s position as a regional hub for pharmaceutical manufacturing and export to regional and international markets, particularly African markets.
During the meeting, discussions addressed the optimal framework for the company’s presence in the Egyptian market, as well as opportunities for pharmaceutical technology transfer and localization.
The legal and regulatory framework governing the manufacturing and circulation of pharmaceutical products in Egypt was also reviewed, including licensing and registration procedures and accreditation requirements in accordance with Egyptian Drug Authority regulations, in addition to the technical and legal requirements necessary for establishing pharmaceutical manufacturing facilities within the Egyptian market.
For their part, representatives of Abdi Ibrahim Pharmaceuticals expressed their appreciation for the role played by the Egyptian Drug Authority in supporting and developing the pharmaceutical sector. They also commended the significant progress achieved within Egypt’s pharmaceutical system at both regulatory and supervisory levels. Furthermore, they affirmed the company’s interest in strengthening its presence in the Egyptian market and exploring opportunities for cooperation in pharmaceutical manufacturing and technology transfer, contributing to the localization of the industry and the expansion of exports to regional markets.
It is worth noting that Abdi Ibrahim Pharmaceuticals is one of the leading pharmaceutical companies in Türkiye and possesses the largest product portfolio in the sector, with more than 500 pharmaceutical products, reflecting its extensive experience and capability to contribute to supporting the localization of the pharmaceutical industry and enhancing exports to regional and international markets.
This meeting comes within the framework of the Egyptian Drug Authority’s efforts to strengthen cooperation with major global companies and support the localization of pharmaceutical manufacturing, contributing to enhancing Egypt’s pharmaceutical security and opening new horizons for exports to regional and international markets.